Future Directions in Myelofibrosis: Implications of Emerging Approaches

This program may include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Myeloproliferative Neoplasms

Diagnosis of Myelofibrosis

MYSEC-MF: A Molecular-Enriched Prognostic Model

Myelofibrosis

Factors Driving Therapy Choice in Myelofibrosis

Clinically Adjusted Treatment of Myelofibrosis

Treatment Algorithm for Anemia in MF

Treatment Is Dictated by Risk Category

MIPSS70 Risk Score: Variables Associated With Reduced OS

Indications of SCT in Myelofibrosis

JAK Inhibitors in Myelofibrosis

Impact on Disease Symptoms and QoL

COMFORT-II: Patient Disposition at 5 Years

JAK Inhibitors in Myelofibrosis

JAKARTA: Fedratinib in Myelofibrosis

Primary Endpoint: Spleen Response (ITT Population)

JAKARTA-2: Open-Label Study With Fedratinib

Fedratinib: Effective Second Line in MF — Results of JAKARTA 2

Review of Encephalopathy Cases

Pacritinib in MF: PERSIST Phase 3 Trials

SIMPLIFY-1: Primary Endpoint, Spleen; Secondary Endpoint, Reduction in Symptoms

SIMPLIFY-2: Primary Endpoint, SRR; Secondary Endpoint, TSS Response Rate

Non-JAK Inhibitors

Molecular and Histologic Remissions With Imetelstat

Pentraxin: Targeting Fibrosis

Sotatercept in MF

Long-Term Outcome of Patients With MPN-Associated Myelofibrosis Treated With Peg-Interferon α2a: FIM Study

Rationale for Drug Combination in MF

Preliminary Results of Ruxolitinib Combinations

JAK Inhibitor Plus Allografting

Preliminary Results of Ruxolitinib Combinations

Unmet Needs

How to Follow and Measure Efficacy

Immunotherapy

Conclusion

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)